Cancers with a specific genetic deletion (9p21 loss) are more likely to be killed by the drugs cytarabine and methotrexate in laboratory models, indicating these drugs might be more effective against this subtype of cancer.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of clinical trials could determine whether patients with 9p21-loss tumors have significantly improved response rates or survival when treated with cytarabine or methotrexate compared to those without the deletion.
A systematic review and meta-analysis of all published prospective clinical trials (n≥10) comparing cytarabine or methotrexate outcomes in patients with 9p21-loss versus 9p21-intact solid tumors, with standardized genetic testing (NGS or FISH), primary endpoints of objective response rate and progression-free survival, and adjustment for tumor type, stage, and prior therapies.
A randomized trial could determine whether adding cytarabine to standard therapy improves survival in patients with 9p21-loss bladder cancer compared to standard therapy alone.
A multicenter, double-blind, placebo-controlled RCT enrolling 300+ patients with advanced 9p21-loss bladder cancer, randomized to cytarabine (100 mg/m² IV daily × 5 days every 28 days) plus standard care vs. placebo plus standard care, with primary endpoint of overall survival at 24 months, confirmed by central genetic testing.
A prospective cohort could determine whether 9p21-loss status predicts better clinical outcomes in patients treated with cytarabine or methotrexate in real-world settings.
A prospective multicenter cohort study following 500+ patients with advanced solid tumors treated with cytarabine or methotrexate, with pre-treatment 9p21 status determined by NGS, tracking response rates, time to progression, and overall survival over 3 years, adjusting for age, tumor type, and comorbidities.
A case-control study could compare the frequency of 9p21 loss in patients who responded to cytarabine versus those who did not, to assess association.
A case-control study comparing 100 patients with advanced bladder cancer who achieved partial or complete response to cytarabine (cases) versus 100 non-responders (controls), matched for stage and prior therapy, with retrospective 9p21 deletion status assessed by FISH or PCR.
A cross-sectional analysis could show the prevalence of 9p21 loss among patients currently receiving cytarabine and correlate it with immediate response metrics.
A cross-sectional analysis of 200+ patients with advanced cancer receiving cytarabine or methotrexate, measuring 9p21 deletion status via biopsy and correlating it with radiographic response (RECIST criteria) at 8 weeks, adjusting for tumor type and line of therapy.